SLP Profile
Simulations Plus, Inc., headquartered in Lancaster, California, specializes in the development of advanced software solutions for drug discovery and development worldwide. Established in 1996, the company operates through two primary segments: Software and Services, catering to a diverse clientele across pharmaceutical, biotechnology, agrochemical, cosmetics, food industries, as well as academic and regulatory agencies.
Under its Software segment, Simulations Plus offers a range of innovative products designed for modeling and simulation in drug development. Key offerings include GastroPlus, which simulates the absorption and drug interaction of compounds in humans and animals, along with DDDPlus, MembranePlus, DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. These products utilize advanced mechanistic and mathematical models enhanced by artificial intelligence and machine learning technologies.
The company's Services segment provides clinical-pharmacology-based consulting services, including population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services to support regulatory submissions. This comprehensive suite of services reinforces Simulations Plus' commitment to delivering tailored solutions that meet the rigorous demands of the drug development lifecycle.
Simulations Plus also offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor (ADMET Predictor) and MedChem Designer, which are chemistry-based computer programs facilitating predictive analytics from molecular structures. With a focus on innovation and scientific rigor, Simulations Plus continues to drive advancements in predictive modeling and simulation technologies, empowering its clients to optimize decision-making processes and accelerate the development of safe and effective therapies.
|
